Marston Linehan:can you all hear me ok? Ok. Thanks, Dr. Passamani,admire the form words and the sort invitation. As Dr. Passamani acknowledged, I work throughout thestreet at the NIH. I’m in the countrywide cancer Institute, and it is excellent to — he asked mebefore this if I had — if i would been to Suburban earlier than. I stated, "good, of path. I are living inBethesda. I’ve been here generally," I was pondering, when he requested me that query.We have two daughters, and once they wereplaying soccer, , they had been continually doing some thing. I might be calling Dr. Goldsteinabout whatever, or an individual about anything, anyone’s ankle or, you know, God knows what.And i brought those kids so most likely to ER, I used to be concerned they have been going to callingthe police or something, you recognize, about some type of abusive dad or mum. I had all these ankleinjuries and all that from soccer.So i’ve quite a lot of — various — I used to think Iowned a wing of this sanatorium after I introduced my children right here so typically. So i have a lotof good associates over right here, and it is nice to see. So what i’m going to speak about — Dr. Passamanimentioned, i am a urologic healthcare professional. And so — and i focus on urologic cancers. So whenyou suppose about urologic, you feel about melanoma generally, urologic cancers make upnearly 25 percent of urologic cancers. If you happen to look at kidney, prostate, bladder, penile,testes, you obtained 24 percentage — 23 percent of human deaths in this country, on this hemisphere,and — incidents — and about 10 percent of deaths. So what i will focus on peculiarly iskidney cancer. Now kidney cancer impacts about close to 300,000 patients worldwide, about 100,000deaths. Within the U.S., sixty five,000 will die of this disease this yr — sixty five,000 will probably be diagnosedthis year, and 13,000 will die of this disease. And there may be about 200,000 patients alive withkidney cancer in the USANow, as Dr. Passamani stated, i am a urologicsurgeon. I’m not a scientific oncologist. I am now not a molecular biologist. However once I camehere, and i got here to NIH, within the early ’80s, I informed, as he stated, Duke Hospitalin Durham, North Carolina. And so if a patient — and this hasn’t modified that a lot betweenthen and now, just a little bit, however — so after we started, a patient involves someone likeme, a urologic medical professional, with a localized kidney melanoma, we take that tumor out surgically,and we may give those patients a 95 percent five- or 10-12 months survival.We do not use theC phrase, the healing word, however, in actual fact, and essentially, I mean, the situation with thisdisease does not return in their lifetime, if you wish to say that. Nonetheless, if patients come to us with advanceddisease, eighty two percentage of these patients will die inside 24 months. So it is an awfully lethaldisease. Among all urologic cancers, kidney melanoma is the one who we are saying fees the most– we used to assert "man years." We now say "person years," in different phrases, factors themost years loss of life considering that you get a variety of kidney cancers earlier in existence, andit’s any such deadly disease.So if you take into account just one thing from thistalk, it is relatively this slide, that kidney cancer is just not kidney melanoma. Kidney canceris a number of one of a kind varieties of cancers. When we started engaged on kidney cancer,it was a single sickness, in the early ’80s, and we dealt with them the entire equal method surgically.We gave them all of the equal medicinal drugs, none of which labored. And we now comprehend that kidney canceris not kidney melanoma. No approach. It’s a number of distinct types of melanoma that simply happento arise in the kidney. They have got distinctive histologies, specific clinical course, respondvery otherwise to remedy.And as i will show you — and i consider is the cause of thislecture sequence — these are precipitated by special genes. So how do you — my God, you are a urologist.You’re speakme about genes. What, have you misplaced your mind? What — I said, "good, lotof men and women are loss of life of this disorder. I can’t feel of a better solution to go than try to understandthe normal cause of these cancers." And so once we started, in reality, nobody had founda human melanoma gene at that factor. And people mentioned to me, [laughs] "Son, you’re over yourhead. I mean, what are you talking about?" folks in my discipline mentioned, "seem, you’re losingit here.No person’s observed a cancer gene. You feel you’ll discover your" — you already know. I mentioned,"good, I — you know, I’ve received a while right here." it’s early in my career, as we say. And Idon’t — I are not able to feel of a greater solution to treat these persons. You realize, at that point,at my first slides, you already know, we’d exhibit, you recognize, 300 medicinal drugs that have been given forthis sickness, none of which labored. So we then headquartered a program on the NCIto gain knowledge of — we determined to make use of — to study households where kidney melanoma runs.So wecould optimistically use the vigour of genetics to identify melanoma genes. So what i’m goingto essentially just stroll by way of with you is our journey over the past 28, 29 years inidentifying these melanoma genes. And as I stated, i’m a urologic healthcare professional. What I — in our laboratory,we’ve, I have no idea, seven hundred mice which have knockout genes. And we’ve got all kinds of celllines growing in a lab and all that. But our major mannequin — our model is the human model.We learn the human mannequin of melanoma.That is it. Any progress we’ve got made has been becauseof that. And so i’m going to sort of stroll you through how — the place we’ve got long gone, andsort of the place we are. So the primary mannequin of inherited kidney cancerwe’d studied used to be one that had been beforehand discovered — described. This used to be describedin 1887. It’s known as Von Hippel-Lindau, or VHL. Von Hippel-Lindau is a hereditary cancersyndrome in which sufferers are at hazard for the progress of tumors in a couple of organs,together with, of path, the kidneys, which is why we bought into this.So these sufferers are at chance to develop bilateralmultifocal kidney cancers. They also get cysts in their kidneys. And the style kidney cancerthey get — in science, we do not say "continually" most often, but this is an continuously. These are alwaysclear telephone kidney cancer. We have now checked out 1000s of these, obviously, at this factor.And they’re continually clear cells — unique varieties. So that’s the most customary type of kidneycancer. Now we set out to take a look at and identify the hereditarygene. The suggestion was once — given that this was before there used to be any Human Genome venture. FrancisCollins was once up in Michigan presently. There used to be no genome software at the time. And itwas relatively a nasty — I imply, it was really rough. And so the pleasant procedure we would thinkof was once to study these households to make use of the power of genetics to take a look at and trace a cancergene via a household.So these patients with VHL — so — but wedidn’t recognize cores. If the hereditary gene — what we had been watching for was the gene thatcaused non-hereditary kidney melanoma. Of direction we’re concerned about hereditary, we’re interestedin any patient with [unintelligible] cancer, most likely. However a long way and — you understand, huge numberof sufferers with non-inherited sporadic kidney melanoma. And we have been looking for the clearcell get probably the most fashioned kind of kidney melanoma. That’s seventy five percent of kidney cancers, whatyou call clear mobile. So we desired to move after that gene. And wehad spent six years engaged on sporadic kidney melanoma, and then run up in opposition to a wall. Sothen we switched and we went to the — be trained hereditary kidney cancers. However we failed to knowif — of direction — if the gene that brought on the hereditary type of kidney melanoma wouldbe the same gene that factors sporadic. That’s not always the case. If you happen to seem at BRCA-1,BRCA-2, the hereditary breast cancer gene, that’s not always the gene that causesbreast melanoma in a woman with breast melanoma, who does not run in the loved ones.So, you understand,you just don’t know. But we figured, well, we are going to move and notice what happens. At leastit’s excellent science if nothing else happens. So — however this was once a excellent form of kidneycancer. So these men and women get up to 600 tumors per kidney. So managing these folks surgically[laughs], you acquired to rethink matters. We’re not curing these people with surgery, certainly,considering the fact that if they’ve 600 tumors, the only method to treatment them is take out their kidney,take out each kidneys, put them on dialysis. And that is what I did with the first patientI had. Sufferer got here with bilateral multi-focal kidneycancer. The traditional way to manage that was to do an nephrectomy. This used to be in theearly ’80s. I noticed a patient from up north, a bilateral multi-focal clear cellphone kidneycancer VHL, talked to all sorts of folks — persons in my subject — read everything,talked to everyone at NIH. The way in which you handled melanoma is you are taking these kidneys out. Youcan’t depart melanoma in there. I did that. And i’ll not ever disregard it. I’ll not ever omit whenthat man left NIH, I took him downstairs in my view to the entrance door and put him in a taxicab.And i despatched that guy dwelling to be on dialysis.And i said, "i’m under no circumstances doing that once more aslong as I reside." So we developed an technique — the managementof these persons — that entails partial nephrectomies. Now, men and women used to suppose clear cell kidneycancer and VHL wasn’t real kidney cancer. Which you could seem at my journal — our journalsin the early ’80s, and also you see journals with titles like "Clear telephone VHL Kidney cancer’sNot actual Kidney cancer." My discipline failed to appreciate the time period "lead time bias." They didn’t understandthat in case you notice a melanoma early, it can be now not always going to be the spreadable moment.You have to provide it time earlier than it is going to spread, like prostate melanoma. A patient to came to us with a massive tumor,about an eight-centimeter tumor, and he or she already had a pulmonary metastasis. We’ve managedmany of those sufferers through the years.We’ve the sector’s greatest experience with this,and we’ve got about 900 sufferers now from about 400 households. And we have now developed an strategy,which I lost quite a lot of sleep over for decades — and that is not casting off theirkidneys, doing partial nephrectomies. In these days, it is rather obvious. But once we started thisin the core Nineteen Eighties, I woke up many, many mornings, many mornings at 3:00 a.M., knowingthat was the day. So what we’d do is we might do partial nephrectomies for tumors smallerthan three centimeter. When we operate, we operate. I imply, we have taken out as many as74 tumors from a single kidney. And i noticed a girl final week where we just lately did theninth operation on her kidney. That’s going the entire method back to ’82 — ’83. Anyway, so we do active surveillance. We watchthese individuals. At the time, individuals in my area — tomatoes, rocks — I can not do not forget whatelse they threw at me.That’s not the way you handle melanoma. And i said, "God, i am hereby myself." At NIH, we now had extra people, however i’m going, "Gee, it’s going to be over,"you recognize. I’d wake up at 3:00 in the morning. I’d come and spot patients that day in medical institution,and i would say — i’d have nightmares that that often is the day i might see — i will stillremember where I was once in mattress when I’d wake up, and that i remembered pronouncing, you realize, "That’sgoing to be the day i will see persons with pulmonary metastasis." And folks aregoing to assert, "You idiot." As of September 6, 2013, we’ve not had one,no longer one single patient enhance metastasis when managed in this fashion. Now have wehad patients with advanced disorder, patients with VHL strengthen metastatic ailment? Yeah,we certain have.We had a bunch. But when the tumors are between three and four centimeters,our metastasis rate is low. It is about four percent. Between 4 and 5 centimeters, they getto be that measurement, it’s about 20 percent. Between — now, whilst you start hitting 5 centimetersand above, it is about 50 percentage. So i will come again to what that could mean in a minute. However anyway, so that is how we manipulate thesepeople. It can be referred to as NINCI three-centimeter rule. Individuals confer with it as that. And we follow this same technique to managingVHL, managing the subsequent disorder — next style of hereditary kidney melanoma, i might say [spelledphonetically] hereditary papillary kidney cancer. And the next one, one known as Birt-Hogg-Dube,however we do not use this procedure for the final two i’m going to exhibit you, which might be exclusive typesof kidney cancer. So the bottom line right here is, is the entire gene.Now we have managed these men and women centered on the gene, and that is it.Now, most of our surgeries now, we do robotic.I desired to exhibit you this one simply to offer you a bit of proposal. So here we’re doing a roboticpartial nephrectomy. This is a kidney melanoma here, a patient with VHL. See the tumor right here?So we’re coming round, and you’re saying, "Wait a minute. I can see that that’s tumor."that is traditional kidney. "you are not getting so much of a margin there, son, are you?" No,we’re now not. We do what we name a nucleation on these. Now, within the historic days — the historical days beingthe ’80s — I used to do wider margins on these. However after a whilst i noticed, "My God,I do vast margin, I got no kidney left." Now — so we now realize quite a bit in regards to the biochemistry,and i will show you a little little bit of that in unique things of these. However this process,we now have now not had a trouble with in a single patient. So we go — we enucleate these tumors.And,as I mentioned, we have taken out up to seventy five, I believe, in a single patient. Whatever likethat, we’d do open. Although robotically, we’re getting so just right — our crew’s gettingso good now — one of the vital fellows did one, I suppose, two and a half weeks ago, we tookout 35 tumors robotically. So as our talent set raises, we’re getting higher and betterand higher at this. And, of path, it can be significantly better for the sufferers if that you would be able to go roboticallythan when you do a huge open operation, which, of path, is what I did perpetually. So we’re proper — as you know, we’re rightacross the road. And this is, of path, the medical institution. So we need to find this gene.So we introduced sufferers in from most commonly U.S., however really world wide. We will carry any individual.And we looked at — we saw households.So we would — how do you do that? So we’d deliver them in, monitor them. Wehave a multidisciplinary workforce that monitors these humans. These people get — also getcerebellar and spinal hemangioblastomas, CNS tumors. We work with our neurosurgeons — sensational.Our retinal — they get retinal tumors. They get retinal angiomas. They get pancreaticendocrine tumors. They get pheochromocytomas — of course, kidney cancers, Epididymal cystadenomas.And so they get a tumor in the meso salpanks [spelled phonetically] of the ovary, it’sa benign tumor. We work — we control them with Dr. Pam Stratton, whose virtually here. So we introduced these people in, and we determinedwho was once affected and who wasn’t in these families. In order that, then, gave us the power of geneticsto hint these genes through these families. Now this took us 10 years to do.We evaluatedDNA from 4,317 sufferers. And we localized this gene, this gene used to be localized right here, tothe — this is chromosome 3. That is what you call the lengthy arm. This is the brief arm,excuse me. That is the lengthy arm. And this is the place we localized it to. Then we mappedand mapped and mapped. And that is what this suggests, our physical mapping. And we identifiedsome candidate cDNAs, some candidate portions of DNA. And then we evaluated them. And this one here was once the seventh cDNA, pieceof DNA, that we checked out and sequenced. And we’re looking for a change in that sequence– anything this is — that segregates with the disease, and that, of direction, is whatwe discovered.This was — this — we called — there wasthe human VHL gene. This used to be the sixth human melanoma gene after we discovered this. And we’relooking for alterations in that gene, mutations. I don’t certainly use the phrase "mutation."What do you imply you do not use the phrase mutation? Well, I had a lady who said to me as soon as, shesaid, "seem, do not name this a mutation." She said, "that is me. That is my family.We now have VHL. My mom had this. My aunt Susie had it. My cousin Fred.My daughter Sarah,and my other daughter Emily, has this. Don’t name us a mutation." I stated, "proper. We’renot." So I say "alteration." So we appear for alteration of those genes thatsegregate with the sickness, and that is what we located. We detected these modifications in365, honestly, and now we’re up to four hundred families. So we’re clearly one hundred percentage. Now we wanted to grasp used to be this the gene welooked for for see you later, for 10 years? Used to be this the gene for the non-inherited kind ofsporadic kidney melanoma? So we took tumors from patients with non-inherited, non-hereditarykidney melanoma, and we look for alteration of this gene, and that’s what we discover. Wefind alteration of the VHL gene in ninety five percentage of tumors from patients with clear cellphone kidneycancer, of the VHL gene pathway. The VHL gene itself about 91 percent. So this is the clear phone kidney cancer gene.We discover these differences in clear telephone kidney cancer, however no longer within the different forms of kidneycancer.So the primary proof that there is a genetic — there’s genetic variations betweenthese special forms of kidney melanoma. So what variety of melanoma gene used to be this? Whenwe found it, it was once a completely novel gene. We had no proposal. Used to be it an oncogene, whichis, you all comprehend, could be a one-hit gene that drives cancer.Or is that this a loss-of-functiontumor suppressor gene? So we every have two copies of each gene: one from our mom,one from our father. These sufferers inherit an alteration of 1 reproduction. And what we showedwas, within the other replica, they lose that. They delete that. So this is what you name a classictwo-hit tumor suppressor gene. This notion of a tumor suppressor gene wasdeveloped via the quality Al Knutson, who’s been our mentor and guide almost 30 years. Alis now ninety, and we went up and did a huge symposium for him. However this can be a two-hit loss-of-functiontumor suppressor gene. Now the other type cancer gene you would thinkabout — and everyone would partner that with Al Knutson — the other variety of geneI’ll show you subsequent is a dominant gene. It is referred to as an oncogene. That’s the place — this isa loss-of-operate.An oncogene is a attain-of-function. So you could have one mutation there. This is atwo-hit gene. This is a one-hit gene, the next one. I will exhibit you that in a 2nd. So, well, that appears excellent, Marston. That’sgreat. Yep. You received that. Runs in men and women’s households. You lose the 2nd replica of thatgene. It will get deleted. But what different — I imply, you say, "That sounds good," but whatevidence do you might have this can be a loss-of-operate gene? Ok, so if we take a cell line from a patientwith kidney melanoma that has a VHL gene alteration, we put that within the lab gorton [spelled phonetically]culture, then we put it in a mouse — an immunocompromised [spelled phonetically] mouse — it goes upand makes a tumor.So that’s what that appears like. And in case you depart it there, it will — whichwe don’t, of direction — in case you go away it there, it should do just what it does in our sufferers.It would spread and kill that mouse. Now, if you’re making one single change, although,in these cells, just one, you are taking the cells and you set in those cells that one gene,only one.And then you develop the cells, put them again in a mouse, you get little or notumor. So that could be a loss-of-perform tumor suppressor gene. So we said, "okay, we’reon the proper path with this gene." Now, once we observed this gene — 1990 — gosh,it is been 20 years now. We located this gene in 1993. We had no thought what this used to be. Itwas a fully novel gene. Humans would say to me, "Marston, gee, you guys are reallythe world’s specialists now in chromosome three.When the Human Genome assignment came, you and yourcolleagues kind of grew to become the go-to people for that chromosome. You going to work onlung melanoma now or something?" No, what are you speakme about? No means. We’re going towork on kidney melanoma. I mentioned, "we will work on this gene." They stated, "well, you’renot a biochemist." I said, "good, we’ll be taught it." And so over time, what we now have learnedis the following. We had no thought how this gene worked. So what we all know now is that theVHL gene makes this protein, VHL protein. And this protein has two domains. One domainbinds these companions right here. We name this the VHL elaborate. And that is what you call anE3 ubiquitin ligase. This can be a very conserved mechanism during biology. Which you could — welearned about this when you consider that we just, of course, discovered this, and then we recognized thatthis protein that I simply confirmed you, this clear cellphone kidney cancer gene, binds thesetwo proteins here — we released that in Science — but it surely failed to help us.We stillcouldn’t determine how this factor was working unless we discovered this gene here cullin 2. So when we determined that, then we had others– we’re then ready to position that collectively, going again and in reality finding out yeast, in case you canbelieve that, that this complicated is what you name an E3 ubiquitin ligase. It is a normalgene, of course, becomes a melanoma gene when it turns into altered. And that this complextargets this loved ones of proteins known as hypoxia inducible element, or HIF, for degradation,for ubiquitin mediated degradation. It places a ubiquitin grouping on right here, and that thendegrades. It can be simply adore it takes these proteins to the trash can, basically. It’s a normalprocess in itself, okay? Besides that is — I bought to learn about this in view that that is criticalto our melanoma. Now the way in which this works is it’s an oxygen sensor.What’s that mean? So when there is a usual quantity of oxygen in the telephone, oxygen in thecell, this elaborate ambitions HIF and degrades it.Now, however, when the mobilephone is shortof breath, hypoxia, it does not have sufficient oxygen, this complex can not goal HIF anddegrade it, and it accumulates. How’s this work? What’s that? Well, HIF is a transcriptionfactor. So it transcribes things. It turns matters on, you would argue. So what it turnson is matters like vascular endothelial progress component. That makes extra blood vessels. Itturns on erythropoietin that makes more pink blood cells. It raises some thing calledplatelet-derived progress factor, which we are going to come again to in a 2nd, PDGF, which tellsthe mobile next door to, you already know, grow, and support us grow. So, basically, you could argue that if youhad a four-12 months-historical child and you took out his correct kidney, his left kidney hypertrophies.How does that happen? Good, you could argue a very good mechanism for that, is the cellbecomes hypoxic — says, "We acquired to develop. We want more blood give. We’d like extra bloodvessels." after which when it will get a bunch of blood to convey oxygens come, and this, that,and the opposite, then it reaches equilibrium in oxygen and turns into normoxic, as we say,after which it kicks again into degrade HIF.That is a horny — it can be just a lovely easy systemonce you realize it. Nonetheless, in our people with kidney cancer,what happens is that they get a metamorphosis in the gene, here in the alpha area, which binds thiscomplex, or the beta area, which is target specificity, which ambitions HIF and degradesit. So what occurs is, in our sufferers with kidney melanoma, you get this mutation clearcell. You get this mutation. And even in natural oxygen, truly the mobile thinks it is shortof breath. That’s almost it. Thinks it can be wanting breath. "I have got to grow. I would like moreoxygen." so as a urologic health care provider, my God, i can understandthis. My tumors are very vascular. This is pronouncing, "We acquired to develop. Obtained to make morevascularity." My tumors are very vascular.My tumors make a variety of erythropoietin, believeit or now not. My tumors stimulate the cells subsequent door. So this, i will be able to fully grasp. So that simpleprinciple, then, is the basis for healing. So you would target this pathway. This isVHL. That is HIF. These are the downstream things I recounted. That is VEGF, plateletdrive progress element. That is an additional one referred to as remodeling development element alpha. Some thing. Anyway, so this is — so that you would targetwith an antibody to target VEGF. That makes sense.Or folks strengthen what are called tyrosinekinase inhibitors, TKIs, a tyrosine kinase inhibitor. I will show you in a minute wherethe tyrosine kinase area — what that suggests. It’s no longer so mysterious, but it surely’s known as aTKI. So these are medicines that target these pathways. So that you might say, "well, we understandthe pathway. Let’s target this pathway in kidney melanoma." So we will fast-ahead a different 10years to today. Good, anyway, a different 10 12 months — good, to today, anyway. In order of today,the FDA has approved seven unique medications towards our first cancer gene pathway. Bevacizumab,an antibody — Avastin, persons call it. Temsirolimus, Everolimus. Sunitinib, Sorafenib. Pazopanib,Axitinib. Now you could argue — well, Sunitinib is right now regarded the high-quality first-linedrug.You get a couple of 25 percentage partial response with that, and a few 20-month disease-freeprogression. The most latest drug goes — you learn New England Journal, article got here outjust lately, inside the previous month, comparing this drug called Pazopanib, and this drug,Sunitinib. And this drug appears equal to this. In clinical oncology lingo, you would say it’snon-inferior, nevertheless it seems to have less toxicity, so this may increasingly in general transfer into first line.So what do I think about this? Good, it makesmy knees vulnerable. I imply, it is — wouldn’t say humbling. It’s incredible that targetingthis pathway, we’re seeing tumors get smaller in people, and we’re extending persons’s lifeexpectancy. And what you can do, then, is that you would be able to sequence these medicinal drugs. You can startwith this, and go to such a different ones or two of those different ones, and perhaps go backto them. So we’re working the discipline — I say "we" — the field is working to make thischronic disorder.Why aren’t we doing better? So that is clear-cellkidney cancer. Why aren’t we doing better, although? We realise this gene. Why can’twe healing this disease? Well, is not it true that these kinds of humans eventually failand die of this disease — die of this — yes, it’s. Okay. So we simply are — so the HumanGenome challenge, the — good, the NHGRI, national Human Genome Institute, and the national CancerInstitute collaborate on a assignment that is referred to as the melanoma Genome Atlas, and we justpublished in Nature just a few months in the past The cancer Genome Atlas of kidney cancer.5 hundredtumors. I had the good fortune to work with the 300 smartest persons I’ve ever met in myentire lifestyles, and did whole genome — you realize, sequencing entire exome, whole genome, allsorts of stuff, and watching at RNA and all sorts of matters, and looking at a entire bunchof kidney — 500 kidney cancers. So the VHL gene has mutated, you understand, herein about 70 percent. In lots of other studies we now have executed, different individuals have executed, it’s reallyhigher than truely that, confirmed about 90 percentage — ninety five percent, if you happen to appear at theVHL pathway. So that is the VHL gene, however these different genes referred to as PBRM1, SETD2, BAP1,they’re additionally mutated, and this gene here, BAP1, seems to be vital in progression.So this gives us new goals. In other phrases, why are not we doing better? Now, one more thing, just to — for those ofyou who want to philosophize about melanoma, this was — this is a paper in New EnglandJournal.I am certain many of you noticed it. It is like in may just of ’12, and it used to be by using an incrediblygifted staff in England at the Wellcome believe. Andy Fatrayal [spelled phonetically] is basicallyhead of this staff, and we all know these guys rather well. And so they checked out a enormous kidneycancer. Now, how long does it take for a kidney cancer to grow, to enhance? Good, for those who’dasked me this about 10 years ago, i might’ve mentioned, okay, so let’s say you could have a VHL — aclear cell kidney melanoma. VHL and non-hereditary are the equal. You had a transparent telephone kidneycancer that is two centimeters in dimension. How lengthy do you consider it’d take to get there — toget two centimeters? Good, i’d have mentioned, "i am lovely experienced on this subject.I’dsay three to 5 years." now not even shut. We now have completed 28,000 tumor measurements. We lookat all these progress premiums, we comply with all these sufferers: 25.2 years to move from zero to two.Now, so should you seem at this tumor that was once 9 centimeters, how lengthy has that boy beenthere? About 30 years, okay? So it causes us to rethink the whole lot we feel, at leastabout my cancers. They’re very — it can be like prostate melanoma. It’s just very gradual-growing. However these humans looked at multiple partsof this 9-centimeter tumor, and they looked at a couple metastases, they usually sequencedall the genes. And what they observed used to be now not shocking to me, but it surely used to be to quite a lot of humans.What they found was once tremendous time heterogeneity. In different words, the gene mutated right here weredifferent than the ones right here and here and right here and here and right here and right here and right here.The genes mutated right here have been pretty much like right here, to the metastases, regular withthey came from one place. Is sensible. And in case you when put next the genomic sample of mutationshere and here, they had been equal to here, assisting that this went there.My God. So how do you — [laughs] — how doyou consider about healing, then, if you are going to goal melanoma genes? My God. Will have to webe sampling a entire bunch of — that is known as — persons call this now "precision treatment,"where you goal a precise gene. And the — one of the vital leaders at our situation said, "well,Marston, you’ve been doing precision medicine for 30 years." I said, "good, maybe." however,anyway, so this is now a massive thrust of mixing genomics, Human Genome project, genetics,with therapeutics in cancer, and something we’re making a big push on. But conceptually, how would you — how doyou consider about this? Should we take a tumor and do a entire bunch of sequencing on a bunchof parts, or will have to we take a metastasis and do a bunch of sequencing, and find, probably,driver — you would name these driver genes.It is an — it is a question no person is aware of theanswer to. I’m going to inform you what I suppose. However, so, these folks when they publish this — I– the guy who did this labored — it is a friend of mine, and that i — he spoke at considered one of my — ourmeeting I sort of aid run. And i said to him after his talk, I said, "Andy, what doesthis mean for cure?" good, he stated, "you’re asking me?" He said, "i’m a genomics guy."I stated, "well, okay." I said, "i’ll let you know what I suppose." but in that — did you readthat? Should you read cautiously that paper in New England Journal, what they stated was theythink what makes essentially the most sense is targeting what’s referred to as the truncal gene, in other words,the VHL gene, which is what we have now continually thought as good.So, you already know, so we willsee. I suppose what i am looking to say is there are complexities in this, and, , wehave miles to head earlier than we sleep. Okay, so that’s the VHL gene. Now the nextgenes i will show you — and that relatively got here from our study of sufferers with non-inheritedkidney cancers. I will show you some other types of kidney melanoma now, and i’malso going to show you one primary theme that runs by way of all cancers, which, to us,is really, we believe, the key to strong therapy.And i’m going to tell you what i go totell you, and that’s, i’m going to inform you that each one these cancers are basically metabolic.They are fundamentally metabolic. So, the whole lot — as I stated, we studypatients. Everything we’ve got realized, now we have realized from sufferers. So this used to be a littlegirl — young lady I noticed in April of ’87. She got here from Ohio together with her mom, her worriedmom, and i took out that left kidney. Tremendous tumor, T3A, 11 centimeters. I received it all out,I inspiration, but she went on to die in January of 1988, that little woman, that young woman.Cheerleader. And that i took the pathology to Maria Marino, our individual pathologist, and that i said,"Maria, what variety of kidney cancer is that?" She said, "Marston, it can be papillary." Yeah,ok. It is not clear, so, no, it’s papillary. All proper. One more little — a further young girl I noticed– this one was once 18, came up from Charlottesville within the spring of ’89.I took out that leftkidney — got here up with her mother, too. I took out that left kidney. She still went on todie in February of 1990. Her mother died 14 months after that of metastatic kidney melanoma, andit took me — took us 18 years to determine what she had. I took the path to Maria, andI stated, "Maria, what is this?" She mentioned, "Marston, it is papillary kidney cancer." All right. 1/3 patient, patient we saw in April — Marchof ‘ninety two. It’s a family, yet another family. This man comes up — this man’s 71. He’s obtained multipletumors in his kidney. Ok. That is his sister, 68, she has a couple of tumors in her kidney.This is his son, 42, there is a couple of tumors in his kidney. I acquired the pathology, I tookit to Maria, I said, "Maria, what is that this?" She said, "Marston, it is papillary kidneycancer." All correct. What i’m going to show you is, sure, it is papillary kidney cancer.Each and every such a is another disorder.It’s one more gene, colossal time differentclinical direction, very distinctive systems to cure. All proper, i will start with the 0.33 one first.So, an extra form of inherited kidney cancer. It is — this hadn’t been described before.We known as it hereditary papillary renal carcinoma. Each and every of those participants in this household havepapillary kidney cancer. This is what you see, bilateral multifocal.This is the firstpatient I saw who — that was once the son, the forty two-12 months-historic. All right. Take into account I informed youabout the 21-12 months-historic? I advised you in regards to the 18-year-historical. My God, I was once worried about thisspreading and killing this sufferer. So I took out this patient’s left kidney right there.That’s the last time we have performed that, undoubtedly for small tumors on this, and i’m going to exhibit youwhy. So that is multiple tumors. This is form 1papillary kidney melanoma. These humans rise up to 1,a hundred tumors per kidney. We manipulate thesethe identical means we control VHL. For this kind of papillary kidney cancer, we all know the genefor it. We watch them. We do this all the time. We watch them, we do lively surveillance,i suppose you might say, unless the largest tumor reaches three centimeters.Then we recommendsurgical intervention. When we operate, we function. We clean that kidney out. But untilthat time, we do active surveillance. Now, the first patient I saw on this was once ’92, soit’s been 21 years. Have we had men and women develop metastatic ailment? Yes we have now. But peoplewith bigger tumors, we have never but had this sort of advance metastatic disease when managedin this fashion, i.E. Active surveillance except the largest tumor is three. So we introduced people in, once more, throughout thestreet — NIH. We did genetic linkage evaluation, localized this gene to chromosome 7. Thisarea right here, we mapped here — it is a really hard area to map — and identified the hereditarypapillary renal carcinoma gene as this, what we call Met, M-E-T. Met. Ok, what’s that?Met is the phone floor receptor for growth component, ligand you wish to have to name it, growthfactor — known as hepatocyte growth component, HGA — HGF. So HGF goals right here, activatesthis, and factors mobile growth. When you don’t need to develop, it stops, and the whole lot’scool until you might have a mutation.It is a single alteration, ok? Single. So this drivecancers to cell — to grow. So this is what you call an oncogene — honestly, a proto-oncogene.It turns into an oncogene with the alteration, however this can be a proto-oncogene, ok? We talkedabout tumor suppressor genes, oncogene. All proper. Good, this — these are the actual mutationswe see in our households. We now have detected — this is a infrequent disease. We have obvious 22 households– detected mutations in all of them. Now, this is — we see this in usually earlyonset — 38-year-historical, 27-12 months-ancient, and we have now obtained a 19-yr-historical in here. So this, targetinga loss-of-function gene in melanoma healing is kind of a — sort of tough. I imply, it can be– targeting a acquire of perform you could argue should simply be tinker toys. I imply,this should simply be screening.I imply, you understand? This is just chemistry. I mean, youought to be ready to do that. So i’m no longer saying that it can be genuine, but conceptually, it shouldbe. So — oh, yeah, I promised you i might — remembera minute in the past I mentioned a tyrosine kinase inhibitor. So that is the gene right here. This is the receptor.This is the extracellular area. This is the trans-membrane area. And this area here– this, you might argue, is the engine room. That is where phosphorylation, which is howyou have an impact on other proteins, form of occurs.That is called the tyrosine kinase area.Tyrosine kinase area. So, you know, if you wish to sound sensible with different people, youcan see, "Oh, these are TKIs." you know, what’s a TKI? Tyrosine kinase inhibitor. K? Somany of the large, you understand, billion, billion, billion buck medications are referred to as TKIs, proper?That’s tyrosine kinase inhibitor. So here I’ve proven you this gene motives this melanoma,and so we want to inhibit this tyrosine kinase area. So we’d like to use a tyrosine kinaseinhibitor. So we did first trial with this drug calledForetinib, which was once a twin kinase inhibitor, a VEGFR, and Met.It had some toxicity wedidn’t like — the VEGFR aspect — and for those who all are medical oncologists, of path youknow this stuff for breakfast and far higher than I do, but you get things like hypertension,malaise, cutaneous, diarrhea, , a number of things can happen with these. Alot of that’s due to the VEGF pathway inhibition. The Met pathway inhibition, we think, is awhole lot less poisonous. We’ll see. So, anyway, so where are we with this? Sowe be aware of the gene, we’ve got a drug that ambitions that pathway. So this patient right here — rememberthe first man that I stated.I took out his left kidney. So that is this man here.So I took out that left kidney in January of 1992. Then in may of 1992, we did a rightpartial nephrectomy and took out 12 tumors from that final solitary right kidney.Guy’s doing satisfactory, goes from side to side to work, little league baseball video games, this, that,and the opposite. We’re not carrying him with this partial nephrectomy. He is acquired this manytumors. So developed — continues to advance tumors, there used to be a wire [spelled phonetically].And in 2000, we took out yet another fifty nine tumors from that final proper kidney.Okay,guy’s doing fine. His renal perform’s a little off, his creatinine’s about 14, EGFR’s about55, however he is doing quality. You already know, you take a seat next to him on a bus, the man looks high-quality.You do not — he’s looking high-quality. However, continues to advance tumor, and tumor now — largesttumor now was 3.Four centimeters. Well, we do not like that. I don’t need him to die of metastaticdisease like his father did. So we put him on drug, and after forty nine cycles of this drug,all these other tumors grew to be undetectable, and this one nearly undetectable. Now we have haddramatic response in the lungs. Folks in clinical oncology correct now, persons in my fieldwill let you know there is not any drug that works in papillary kidney cancer. That is papillarykidney cancer. Now, that is what you call a waterfall plot.So this shows the scale back of these tumors.Now a lot of [unintelligible] experimentalthing, works first time, and all that variety of stuff. Numerous these folks I had — wehad heavily operated on. They may be heavily pretreated with surgery. Many had marginal renal operate,and plenty of had to come off drug for all different types of nickel dime motives. However each single tumor,every single tumor, bought smaller throughout therapy. So this proof of principle that targetingthis melanoma gene might influence these cancers. So are we home? No, we’re no longer dwelling, however we’reencouraged about the progress of the work. Our next trials are going to contain specificTKIs, tyrosine kinase inhibitors, that just hit Met. And then we’ve got a quantity of otherthings that in a lab look sensational against this pathway targeting Met, and we’re goingto be sequencing these trials and we will be able to hope. But i am hopeful. I’m confident. Now how about this little girl? This is thefirst one I showed you, this 21-year-old cheerleader from Ohio who had papillary kidney melanoma.So we took that out, I put that — we put that in tradition, and we grew it in a lab.And we showed a humorous chromosomal pattern.We confirmed that a part of the first chromosometranslocated to the X chromosome. I’ve obtained to move. And this translocation worried agenome chromosome one and the X chromosome gene known as TFE3. So that is like many leukemias.This is a fusion melanoma. So — and it is very aggressive. We noticed a 23-yr-historical the opposite day, legislation scholar,with this very small tumor, already had local nodes. This you do not do active surveillanceon. These unfold early. That is referred to as TFE3 kidney melanoma. It now makes up about 1.5 percentof all tumors, but 20 to forty five percent of tumors in younger people.We now understand this is a household.Due to this fact, TFEB has been found out, which is another form of very identical kidney melanoma,in most cases in youngsters, and one other one is MITF — a different member of this family, and that gene is mutated,and this can run in families. So i will scroll via this and talkabout this one. This is known as Birt-Hogg-Dube. It is a hereditary cancer syndrome wherepeople get dermis bumps. They get fibrofolliculoma, benign hair follicle tumors. Runs in households.We showed these persons additionally get kidney cancers. They get unique varieties of kidney melanoma.They may be able to get clear phone, they are able to get whatever known as hybrid oncocitic, they may be able to get chromophobekidney melanoma. They stand up to 3,000 tumors per kidney. We manipulate these the same means:three centimeters, lively surveillance. So we introduced these households in, searchedfor this gene, used the dermis marker, the fibrofolliculomas, the benign dermis lesions, as a marker to tracethe gene in the family, identified it on chromosome 17 in this area right here. That is thegene. We name it FLCN. That is the BHD gene. We’ve got detected mutation on this now in 97percent of those families.These men and women additionally — this is pretty normal. You’ll be able to see these,those of you who are urologic surgeons, in case you are. So that they get multiple cysts in thelungs. Thirty percentage of these folks get pneumothorax. We desired to know what kindof gene this is. I’m going to monitor via this due to the fact that we’rerunning wanting time right here, and in actual fact to exhibit you that once this gene is mutated,it activates two fundamental cancer pathways referred to as mTORC1 and mTORC2. K? How’s thathelp me? All proper, in view that there are medications that target these pathways. So in this mousemodel here, we knocked out this gene in mice, the identical human kidney melanoma gene within the mouse– in the kidney of a mouse, and what we get there’s we get a enormous kidney, a cyst. They’restarting to kind little tumors, however they die of kidney failure in 30 days before they getkidney cancer, they get full-blown kidney cancer. So I said, "All right. How about ifwe deal with these guys?" So these guys died about 30 days of kidney failure.So I dealt with theseguys with this drug — sincerely, Rapamycin, which objectives that pathway I showed you, andwe noticed a dramatic outcome. We doubled their existence expectancy. So that’s focusing on thispart of the pathway, and we’re now gearing as much as do medical trials in people hittingboth this section and this section. Now, in closing, i will show you this last patient.This used to be this little 18-12 months-historical, got here up from Charlottesville together with her mother. You recognize,we — you under no circumstances — i do know you’re the equal.You not ever fail to remember a sufferer. You already know, thisis — it took us 18 years to determine what this was once in her. In ‘ninety five, we described anothertype of hereditary kidney cancer that was once redescribed and renamed in ’99, and now goesby the term hereditary leiomyomatosis renal cell melanoma. This men and women get cutaneous leiomyomas.They get epidermis bumps. They are little muscle tumors, they usually get uterine leiomyomas — somepeople name these fibroids — and they get kidney melanoma. Runs in households, autosomaldominant, and these are traces in these families. These are these, quote, "epidermis bumps," andthey can be very variety of — these are benign, although many pathologists get them confusedfrom leiomyosarcoma since the pathology’s slightly fussy. However — and what these are, are the next.These are little muscle tumors, and so if this is a hair follicle, there may be a muscleunderneath it referred to as a rector p-gentle [spelled phonetically].So whilst you go out on a coldmorning, and it can be cold and you get goosebumps, it’s that muscle. That muscle is an energysensor. It senses that you’re in need of energy, because it were — vigor in the cell called ATP,and it contracts. All correct? That is the identical muscle a porcupine uses to fire his quills. Now, these can also be, in these sufferers, reallybad. They may be able to be very painful. We now have lost one. Or we had one — genuinely, it used to be a familymember of certainly one of ours, committed suicide, and we now have had another one who’s — we’re concernedabout. Anyway, they are able to be — they may be able to be very symptomatic. In many instances they are no longer symptomaticat all. Generally you wouldn’t have these. But — and it’s specially — I’ve obtained one now.It is a college pupil in Boston, and acquired the disorder right here. Whenever it is cold, he won’tgo to classification. He also gets embarrassed. I mean, it’s — we’re working on it. But anyway, sothat’s the dermis manifestation, and it is a splendid one.This is — they get cutaneousleiomyomas, and it is early onset. And we control these sufferers with Dr. Pam Stratton, oursensational colleague who’s particularly the world’s informed on this — managing these patients. So after we saw our first sufferers, and wereported them — so we seem at this. Ninety percent of the women have fibroids. That is,by the way, now not that distinct a disease. I believe you will see this at Suburban clinic.I do know for definite many hospitals — i can believe of many hospitals [unintelligible].So you’llsee these sufferers. Now, it can be early fibroids. In our preliminary record, 90 percent of the womenget these early onset fibroids and are firstly is a catastrophic — generally is a catastrophicphenotype for females. Fifty percentage of our females in our first file had hysterectomiesin their 20s. So we hate this. So now, we and others — I say "we" — NIH and others,Dr. Stratton and her colleagues, are doing myomectomies, and that i believe now she has, I suppose,4 sufferers who’ve had toddlers after that, and we’re very pleased with that. However this isa very dominant phenotype. Now, we bought into it seeing that of this, most likely, the kidneycancer. So this patient right here, that 18-year-historical I mentionedto you — I lost her.Her mom died. God, i attempted for years to seek out her. This used to be in Charlottesville.We found out 18 years later that what occurred was her siblings moved in with the fatherwho had one other final title. The moms and dads have been cut up. And between then and once we foundthem, the brother died, her uncle died, aunt died, uncle died. We observed them when we sawthis one, who then went on to die, got here to us with very evolved sickness. This is a verycatastrophic phenotype if now not diagnosed and dealt with. If you happen to deal with it, you are just right. It is a very — that is the second patientI saw, a 21-year-old got here to me with this tumor here, got here up from — Cuban descentfrom Miami, and i took this out.I do know, aggressive melanoma, but i’m good. He died 17 months laterof metastatic disorder. This man came to us — 32-12 months-ancient whose father had died of metastaticcancer. You will see the skin bumps right here. It can be quite — we don’t have an understanding of this yet. [laughs]it’s rather outstanding. They don’t pass the mid-line. They discontinue correct in the mid-line.Boom, seem at that. You can find we biopsied this guy, and after we screened him — oh,he’s an asymptomatic man, doing best, 32. Once we screened him, we observed they can getcysts in their kidney, and they can get tumors within the cysts, and they can get just plaintumors, as it have been, and they can get simply simple cysts.We go crazy over managing thesepeople. I imply, we agonize over them. So this guy had cyst, however he had tumor insideit. I will show you that. Doing quality. Very small tumor, half centimeter, one half centimeter.After we took this out, one can find it can be a half centimeter, the leisure of it was totallycystic. But he already had a colossal, optimistic node. These unfold early. You do not do activesurveillance, and also you ought to reveal them each 12 months. Every yr, MRI. These can also be– it can be an wonderful style, of path, of papillary kidney melanoma with these distinguished — ourcolleagues in — if we’ve any in the viewers who are pathologists — would inform us theseare outstanding nucleoli, and they would describe this as perinucleolar halo. So it’s a verysort of characteristic pathologic phenotype. Whenever you see it, you can make the diagnosison this. Maria Marino, our unusual pathologist, shelooks at that and he or she says, "this is it." She’s batting 100 percentage.So — but thiscan be early onset, too. We’ve got got this in youngsters, 10-12 months-historic got here to us with this. Bigtumors. We have obvious it first time in a 77-year-historical. I mean, his first tumor. These persons areat chance for multifocal and bilateral. That is Sophie’s alternative. What, do you’re taking outthe kidney? Horrible melanoma. What are you going to do? So how will you control them? So thispatient right here, 24, involves us with this.So you get this CT. I do not know. I cannot callanything in that. That’s a cyst. There anything in there, i’m now not — i do not. Do an MRI. Good,I have no idea. Is that only a cyst? Is that quantity averaging? I have no idea. Come again– come again in 9 months, we are going to get a brand new CT and a brand new MRI. Obtained a CT. Nothing, that’snothing. I don’t — just a cyst, right? MRI, increase. We call that a double bump. See that?So we stated, "We’re operating." when we function — bear in mind I confirmed you howwhen we did the VHLs, clear mobile kidney, we know the gene, be aware of the pathway, understand theygrow sluggish. We just did nucleation here. No method. So right here, we go wide, huge time. Why don’tyou simply do a nephrectomy, Marston? Good, we don’t [laughs] — these individuals are at riskfor multifocal. I do not wish to be just whipping out these kidneys. So we do partial, but — andwe’ve had number of patients come to us, the place persons simply did your typical partial, and itwas a disaster.And this lady shows you why. So we went manner large. We went all the approach upto the hilum of the kidney. We dissected out the hilum, did very, very wide operation;did really close to a heminephrectomy on that. So, Maria Marino appeared at the direction, I proposal,she used to be, she said, I idea she was once going to throw up. She said, "Marston, you’ve gotto come over and seem at this." mentioned, "you know, your little girl, is it 24-year-old?"I stated, "Yeah." I said, "The one with the cyst, and the tumor within the cyst?" She stated,"Come over here." I said, "All proper." She mentioned, "appear.See this course?" I said, "Yeah."She mentioned, "this is your tumor. This is the cyst; this is your tumor." mentioned, "however lookat this. That is the ordinary kidney. It can be infiltrated all up into the ordinary kidney." I stated, "Don’ttell me my margin’s no longer easy." She mentioned, "No, your margin is fine." She stated, "Youdid a colossal margin." [laughs] I stated, "Yeah." She stated, "you’ve two centimeters cleanhere." She mentioned, "however this thing –" she said, "This factor used to be invading the entire approach up intothe periculum." I said, "Maria, I knew that. I mean, I sensed that, however we could not seeit. You can’t see it on imaging; nobody can. She stated, "well, it is a nightmare." Now, she’s high-quality. That is ’08, and we’re nowfive years out. She’s sickness-free, doing pleasant.However we have now had a number of patients whocame in after simply partials, simply ordinary partials. Nightmare. Positive margins, diseasespread. When you spill these cells, it’s unhealthy information bears. So that you got to be actual carefulhow you manipulate these people. So, well, what are you going to do? Simply waituntil stuff happens? No. We’re going to photo these men and women every year. So, here’s a woman we saw. Got here up from Baltimore.In ’03, we noticed her. She’s germ-line confident for this disorder. We informed her that imagedevery — we encouraged imaging every year.Some thing cause, wasn’t accomplished. In ’06, shehad imaging which used to be called usual. Then, in — right before Christmas, correct beforethe vacation trips in ’10, I bought a call from guys at Maryland — school of Maryland. Theysaid, "Marston, now we have acquired certainly one of your over right here." She didn’t have screening in four years.That is what she had then. We took this out in January, you realize, correct after the vacation.Ten of 59 nodes positive. We now — she’s now in considered one of our therapeutic trials, actuallydoing very well with metastatic melanoma. Once we first saw her, she had no sickness. So we do not do active surveillance. And whenwe do surgery, we go broad. We do not do any of these robotic. We go broad. I don’t wantto do — I wish to go open and go wide on these.They also may also be multifocal, so wehave to be real cautious about them. This gene is on chromosome one. This is what the geneis. It’s a Krebs cycle enzyme called fumarate hydratase, which takes you from fumarate tomalate. I know we’ve got obtained to — now we have received to stop, so i’m going to — i’ll justabbreviate this. To make an extended story short, we had mutationsin all of these cancers. It is a very aggressive cancer wherein the metabolic — these tumorsundergo a metabolic shift. This is the TCA cycle to glycolysis. And make an extended storyshort, via working out this pathway, we’re focusing on this with bevacizumab and erlotinib,and we’re seeing very — I misplaced each one of these sufferers except just recently, untilwe began doing this. This we do with Rom Srinivasan, scientific oncologist, works withus.And we have seen rather dramatic response in sufferers. This woman right here, both her sisters died, fatherdied of metastatic kidney cancer. She got here to us with developed sickness after a partialnephrectomy, in which disease used to be left behind. And it spread all during her retroperitoneumabdomen. We put her on this therapeutic approach. In three months, she was once a complete response.It can be now seven years; we can’t in finding ailment. We don’t use the "C" phrase, the treatment phrase,however we’re at seven years. It can be surely seven now. So, what i am — went via plenty of things,but the fundamental factor is kidney melanoma is basically no longer kidney melanoma. It is anumber of distinct types of cancers prompted through — with distinct histologies, differentclinical path. I showed you a little bit about distinct tactics to remedy, howdifferent they are, figuring out the gene for these cancers, and that they are prompted by differentgenes. So I want to well known my colleague, PeterPinto, Adam Metwalli, Piyush Agarwal, Rom Srinivasan, our medical oncologist, world’sbest urologic oncology fellows, and the complete Urologic Oncology application, and likewise the othercolleagues in gynecologic surgical procedure, neurosurgery, ENT, ophthalmology, endocrinology, endocrinesurgeon — endocrine surgical procedure, that we’ve got the distinction to work with.So, are we home yet? No, we’re now not. But I’moptimistic. And, again, i am such as you. I’m a general practitioner. We take our sufferers like everyonedoes. And everything we’ve got discovered, we have realized by finding out these sufferers. That’swhere the whole lot we know has come from. Every single thing. Are we house? Are we there but?No. But i’m constructive, and i’m hoping to are living to see it. Thanks very so much. [applause] Male Speaker:we have time for a few feedback and questions. I have one. Marston, I appreciate why you’rereal careful of not having a enormous margin in clear cells. What’s with that tumor that letsyou do this? Marston Linehan:well, it’s just that it is — that — well, that’s an excellent question.It can be just thatit’s a sluggish-developing tumor. It hasn’t developed the equipment to invade yet, until you geta designated point in time. Now, you — it — there’s complexity in existence. And the complexityin unraveling all these questions is style of the next. Now, I hate it when I seea sufferer with metastatic melanoma, you already know? We all do. You hate it when a pal, or anyone’sspouse, or, you already know, it is just — you already know, you hate it. However, you say to your self, "That’san altered gene." And genes alter at a designated predictable fee. Ten occasions 9 for celldivisions, on common, you get a gene alteration. Now, you could argue — it can be not, surely,it’s no longer an argument. Good, until you are into scientology, i assume, or something. However,if it weren’t for that, we wouldn’t be here? As Norman, I think it was once Norman Thomas said,"If it weren’t for that, there wouldn’t be any music." In other phrases, we might all be single-cellorganisms.If it weren’t for alteration in genes with telephone division, there could be nohumans. There would be no birds. So — but it surely’s that identical mechanism that reasons melanoma. Now, there’s a common exchange — price — changeof genes in a cancerous cellphone. Now, that sufferer from the brand new England Journal article had beenthere 30 years as a minimum. A natural phone simplest lives seven telephone cycles, and then it turnsover, correct? But these cells grew to be immortalized 30 years ago, so they are going to decide upon upall forms of stuff along the way in which. Now, i might like to assert your tax dollars [laughs] aregoing toward figuring out that. In order words, there is a entire lot of changes while you dowhole-genome sequencing, and, oh, appear in any respect these genes. However figuring out which ones are,you need to say drivers, and who’s passengers, good, that’s where it takes considerate science Male Speaker:it is particularly happenstance that you rather desired to hold kidney operate.That made youmake — do that experiment, I feel. Marston Linehan:Yeah, well, you are — well, you’re right about that. Yeah, you’re right about that. Male Speaker:other unanswered questions? If now not, I want to thanks for a exceptional presentation,and we can discontinue now. Marston Linehan:make an apology for going over. [applause].